Aclaris Therapeutics, Inc. (LON:0H8T)
London · Delayed Price · Currency is GBP · Price in USD 2.495
-0.040 (-1.58%)
At close: Nov 3, 2025
Aclaris Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 16.79 | 18.72 | 31.25 | 29.5 | 6.64 | 6.48 | Upgrade |
Other Revenue | - | - | - | 0.26 | 0.12 | 0.01 | Upgrade |
| 16.79 | 18.72 | 31.25 | 29.75 | 6.76 | 6.48 | Upgrade | |
Revenue Growth (YoY) | -47.56% | -40.09% | 5.03% | 340.05% | 4.30% | 53.35% | Upgrade |
Cost of Revenue | 53.09 | 49.04 | 114.25 | 89.77 | 48.53 | 34.47 | Upgrade |
Gross Profit | -36.3 | -30.32 | -83 | -60.02 | -41.77 | -27.99 | Upgrade |
Selling, General & Admin | 22.13 | 22.2 | 31.51 | 25.13 | 23.62 | 20.53 | Upgrade |
Operating Expenses | 22.13 | 22.2 | 31.51 | 25.13 | 23.62 | 20.53 | Upgrade |
Operating Income | -58.43 | -52.53 | -114.51 | -85.15 | -65.38 | -48.52 | Upgrade |
Interest & Investment Income | 8.28 | 7.95 | 8.51 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 3.71 | 1.91 | - | 2.95 | -1.14 | -0.42 | Upgrade |
EBT Excluding Unusual Items | -46.45 | -42.66 | -106 | -82.21 | -66.53 | -48.94 | Upgrade |
Merger & Restructuring Charges | - | - | -3.12 | - | - | - | Upgrade |
Other Unusual Items | -1.3 | -2.5 | 26.9 | -4.7 | -24.34 | -2.39 | Upgrade |
Pretax Income | -134.65 | -132.07 | -88.85 | -86.91 | -90.87 | -51.34 | Upgrade |
Income Tax Expense | - | - | -0.37 | - | - | -0.18 | Upgrade |
Earnings From Continuing Operations | -134.65 | -132.07 | -88.48 | -86.91 | -90.87 | -51.15 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | 0.14 | Upgrade |
Net Income | -134.65 | -132.07 | -88.48 | -86.91 | -90.87 | -51.02 | Upgrade |
Net Income to Common | -134.65 | -132.07 | -88.48 | -86.91 | -90.87 | -51.02 | Upgrade |
Shares Outstanding (Basic) | 103 | 77 | 70 | 65 | 57 | 43 | Upgrade |
Shares Outstanding (Diluted) | 103 | 77 | 70 | 65 | 57 | 43 | Upgrade |
Shares Change (YoY) | 44.96% | 10.73% | 7.05% | 14.95% | 33.36% | 2.94% | Upgrade |
EPS (Basic) | -1.31 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | Upgrade |
EPS (Diluted) | -1.31 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | Upgrade |
Free Cash Flow | -10.05 | -20.2 | -79.63 | -68.17 | -52.44 | -39.09 | Upgrade |
Free Cash Flow Per Share | -0.10 | -0.26 | -1.14 | -1.04 | -0.92 | -0.92 | Upgrade |
Gross Margin | -216.22% | -161.99% | -265.60% | -201.74% | - | - | Upgrade |
Operating Margin | -348.04% | -280.59% | -366.44% | -286.21% | -967.08% | -748.52% | Upgrade |
Profit Margin | -802.03% | -705.48% | -283.15% | -292.11% | -1343.96% | -787.03% | Upgrade |
Free Cash Flow Margin | -59.87% | -107.89% | -254.84% | -229.13% | -775.65% | -602.99% | Upgrade |
EBITDA | -58.26 | -52.22 | -114.45 | - | -65.06 | -48.2 | Upgrade |
EBITDA Margin | - | -278.95% | - | - | - | - | Upgrade |
D&A For EBITDA | 0.18 | 0.31 | 0.06 | - | 0.32 | 0.32 | Upgrade |
EBIT | -58.43 | -52.53 | -114.51 | -85.15 | -65.38 | -48.52 | Upgrade |
EBIT Margin | - | -280.59% | - | -286.21% | - | - | Upgrade |
Revenue as Reported | 16.79 | 18.72 | 31.25 | 29.75 | 6.76 | 6.48 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.